Dividend Authorizations, Leadership Appointments, and Scheduled Conferences - Analyst Notes on Thermo Fisher, PAREXEL, Quintiles, Alere and PerkinElmer

NEW YORK, May 30, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Thermo Fisher Scientific, Inc. (NYSE: TMO), PAREXEL International Corporation (NASDAQ: PRXL), Quintiles Transnational Holdings Inc. (NYSE: Q), Alere Inc. (NYSE: ALR) and PerkinElmer Inc. (NYSE: PKI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3112-100free.

--
Thermo Fisher Scientific, Inc. Analyst Notes
On May 21, 2014, Thermo Fisher Scientific, Inc. (Thermo Fisher) announced that its Board of Directors has authorized and declared a quarterly cash dividend in the amount of $0.15 per share. According to the Company, the dividend is payable on July 15, 2014, to shareholders of record as of June 16, 2014. The full analyst notes on Thermo Fisher are available to download free of charge at:

http://www.analystsreview.com/TMO.pdf/Register

--
PAREXEL International Corporation Analyst Notes
On May 27, 2014, PAREXEL International Corp. (PAREXEL) announced the appointment of Dr. Sy Pretorius as the Company's Chief Scientific Officer wherein, he will be responsible for enhancing and leading innovation of clinical research methodologies, and helping the Company to further integrate its offerings in order to meet the growing industry demand for end-to-end drug development services. PAREXEL informed that Dr. Pretorius who currently serves as the Company's Corporate Vice President and Worldwide Head of Early Phase, will continue his responsibilities in that role in addition to assuming his expanded responsibilities as Chief Scientific Officer. Mark A. Goldberg, M.D., President and Chief Operating Officer, PAREXEL said, "Customers are increasingly seeking a full spectrum of integrated clinical research services from a single provider to make drug development more efficient." He continued, "Sy Pretorius has enjoyed a long and distinguished career at the Company, and applying his expertise more broadly will benefit customers and PAREXEL alike." The full analyst notes on PAREXEL are available to download free of charge at:

http://www.analystsreview.com/PRXL.pdf/Register

--
Quintiles Transnational Holdings Inc. Analyst Notes
On May 27, 2014, Quintiles Transnational Holdings Inc. (Quintiles) announced that the Company is scheduled to present at the Goldman Sachs 35th Annual Global Healthcare Conference on Wednesday, June 11, 2014, at the Terranea Resort in Rancho Palos Verdes, California. The Company informed that its CEO Tom Pike will present at 1:20 p.m. PDT and the live audio webcast of the presentation will be available on the Quintiles' Investor Relations website. The full analyst notes on Quintiles are available to download free of charge at:

http://www.analystsreview.com/Q.pdf/Register

--
Alere Inc. Analyst Notes
On May 15, 2014, Alere, Inc. (Alere) announced a quarterly cash dividend in the amount $3.00 per share on its Series B Convertible Perpetual Preferred Stock. The Company informed that the said dividend is payable on July 15, 2014 to shareholders of record of Series B stock at the close of the business on July 1, 2014. Alere added that the stated dividend payment will cover the amount of all dividends which accrued from April 1, 2014 through June 30, 2014. The full analyst notes on Alere are available to download free of charge at:

http://www.analystsreview.com/ALR.pdf/Register

--
PerkinElmer Inc. Analyst Notes
On May 27, 2014, PerkinElmer, Inc. (PerkinElmer) announced that it has scheduled to present at the Goldman Sachs Global Healthcare Conference on June 10, 2014, at 9:20 a.m. PT at Terranea in Rancho Palos Verdes, California. The Company informed that in the presentation, Robert F. Friel, PerkinElmer's Chairman and CEO, will provide an overview of the Company and its strategic objectives. PerkinElmer added that a live audio webcast of the presentation will be available on the investor section of the Company's website. Additionally, a replay of the webcast will be available for two weeks at the Company's website. The full analyst notes on PerkinElmer are available to download free of charge at:

http://www.analystsreview.com/PKI.pdf/Register

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED